PSPuja Sakhuja

Puja Sakhuja

*This is an algorithmically generated author record based on publicly available information.

Puja Sakhuja has a total of 140 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Adenomyomatous Hyperplasia of the Vaterian System: The Hidden Culprit Behind Whipple Procedures

    by Bharathi Prabakaran, Kumble S. Madhusudhan, Rajesh Panwar, Asuri Krishna, Hemanga K. Bhattacharjee, Sweta Bhartiya, Venu Madhav Jarapala, Rajni Yadav, Pooja Sakhuja, Anil Kumar Agarwal, et al.

    Introduction: Adenomyomatous hyperplasia (AH) of the Vaterian system is a rare benign lesion, often clinically mistaken for carcinoma and leading to unnecessary Whipple surgery. Methods: In this multicentre cohort, Whipple pancreaticoduodenectomy specimens were identified and operated on with a clinical diagnosis of ampullary tumor, which on histological examination, however, showed AH, collected over 3 years (2022-2024). In this retrospective observational study, we analyzed the clinico-radiological and histological details of 12 of such patients and described them here. Results: In these 12 patients with pancreaticoduodenectomy, the mean age was 51.7 years (range 29 to 63 years) with a male-to-female patient ratio of 9:3. Although abdominal pain was the most common presentation (11/12 patients); obstructive jaundice occurred in two. The preoperative imaging revealed common bile duct dilatation (11/12) and double duct sign (6/12), with the suspicion of carcinoma in all. Grossly, the lesions measured 0.4 to 4.3 cm (median 1.4 cm), six centered on the ampulla, others extending to the pancreatic head or the distal bile duct. Microscopy showed bland mucous glands, smooth muscle, and fibroblasts; immunohistochemistry confirmed keratin 7, MUC6, MUC5AC, and actin positivity. Ki-67 index was low. No recurrences occurred during 6-48 months follow-up. Conclusions: Clinicoradiologically, ampullary AH mimics ampullary malignancy. However, AH should be considered in the clinicopathologic differential diagnosis of ampullary lesions.

  • Open Access

    A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF

    by Virginia Hernandez-Gea, Valerie Paradis, Maha Guindi, Venancio A. F. Alves, Amal Aqul, Eira Cerda, Sarwa Darwish Murad, Prasenjit Das, Angelo Di Giorgio, Luiz A. R. de Freitas, et al.

    Noncirrhotic portal hypertension has historically been described using heterogeneous and region-specific terminology—such as idiopathic portal hypertension (IPH), noncirrhotic portal fibrosis (NCPF), obliterative portal venopathy, and nodular regenerative hyperplasia—leading to substantial variability in diagnosis, reporting, and international research collaboration. Differences in guideline definitions from major societies (AASLD, EASL, and APASL), together with the presence of characteristic histologic lesions in patients without clinically overt portal hypertension, have further complicated disease classification. To address these challenges, a large, multisociety, international initiative was convened to harmonize nomenclature and diagnostic criteria. Representatives from liver, pathology, and pediatric hepatology societies across the Americas, Europe, and Asia participated in a structured consensus process that included specialized working groups and external Delphi validation. The initiative produced a globally harmonized and implementable diagnostic framework. Consensus was reached that the terms porto–sinusoidal vascular disorder (PSVD) and NCPF may be used interchangeably when identical diagnostic criteria are applied, and that they should be written as PSVD or NCPF. The diagnosis was defined as fundamentally clinicopathological, requiring integrated assessment. Core principles include the need for a high-quality liver biopsy (≥10 mm), mandatory exclusion of cirrhosis, and systematic exclusion of specific alternative conditions. Importantly, the consensus recognizes that PSVD or NCPF may be diagnosed even without clinical portal hypertension and may coexist with other liver diseases, provided cirrhosis is excluded. Standardized major and minor histologic criteria were developed collaboratively by expert pathologists and externally validated. Features of portal hypertension were harmonized into specific and nonspecific categories applicable to routine clinical practice. An integrated diagnostic scoring system incorporating histology, clinical features, associated conditions, and concommitant etiologies was developed and validated using the Delphi method. This consensus provides the first internationally endorsed, unified framework for the diagnosis of PSVD or NCPF. Its global implementation is expected to reduce diagnostic variability, improve comparability across regions, and facilitate the development of robust, internationally harmonized clinical and translational research cohorts.


  • Open Access

    A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF

    by Virginia Hernández-Gea, Valerie Paradis, Maha Guindi, Venancio A.F. Alves, Amal Aqul, Eira Cerda, Sarwa Darwish Murad, Prasenjit Das, Angelo Di Giorgio, Luiz A.R. de Freitas, et al.


  • Open Access

    A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF

    by Virginia Hernandez-Gea, Valerie Paradis, Maha Guindi, Venancio A.F. Alves, Amal Aqul, Eira Cerda, Sarwa Darwish Murad, Prasenjit Das, Angelo Di Giorgio, Luiz A.R. de Freitas, et al.

  • Open Access

    A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF

    by Virginia Hernandez-Gea, Valerie Paradis, Maha Guindi, Venancio A.F. Alves, Amal Aqul, Eira Cerda, Sarwa Darwish Murad, Prasenjit Das, Angelo Di Giorgio, Luiz A.R. de Freitas, et al.

    Noncirrhotic portal hypertension has historically been described using heterogeneous and region-specific terminology—such as idiopathic portal hypertension (IPH), noncirrhotic portal fibrosis (NCPF), obliterative portal venopathy, and nodular regenerative hyperplasia—leading to substantial variability in diagnosis, reporting, and international research collaboration. Differences in guideline definitions from major societies (AASLD, EASL, and APASL), together with the presence of characteristic histologic lesions in patients without clinically overt portal hypertension, have further complicated disease classification. To address these challenges, a large, multisociety, international initiative was convened to harmonize nomenclature and diagnostic criteria. Representatives from liver, pathology, and pediatric hepatology societies across the Americas, Europe, and Asia participated in a structured consensus process that included specialized working groups and external Delphi validation. The initiative produced a globally harmonized and implementable diagnostic framework. Consensus was reached that the terms porto-sinusoidal vascular disorder (PSVD) and NCPF may be used interchangeably when identical diagnostic criteria are applied, and that they should be written as PSVD or NCPF . The diagnosis was defined as fundamentally clinicopathological, requiring integrated assessment. Core principles include the need for a high-quality liver biopsy (≥10 mm), mandatory exclusion of cirrhosis, and systematic exclusion of specific alternative conditions. Importantly, the consensus recognizes that PSVD or NCPF may be diagnosed even without clinical portal hypertension and may coexist with other liver diseases, provided cirrhosis is excluded. Standardized major and minor histologic criteria were developed collaboratively by expert pathologists and externally validated. Features of portal hypertension were harmonized into specific and nonspecific categories applicable to routine clinical practice. An integrated diagnostic scoring system incorporating histology, clinical features, associated conditions, and concommitant etiologies was developed and validated using the Delphi method. This consensus provides the first internationally endorsed, unified framework for the diagnosis of PSVD or NCPF. Its global implementation is expected to reduce diagnostic variability, improve comparability across regions, and facilitate the development of robust, internationally harmonized clinical and translational research cohorts.


  • Open Access

    Protein Expression Analysis and Functional Characterization of Sorcin in Gallbladder Cancer

    by Vaishali Jain, Neeraj Saklani, Srishti Kawatra, Puja Sakhuja, Surbhi Goyal, Anil Kumar Agarwal, Parveen Kumar, Fouzia Siraj, Poonam Gautam

    Gallbladder cancer (GBC) is an aggressive malignancy with limited treatment options and poor clinical outcomes. Identifying novel molecular targets is critical for improving therapeutic strategies. Sorcin (SRI), a calcium-binding protein implicated in tumor progression, has not been comprehensively investigated in GBC. SRI expression was analyzed by immunohistochemistry (IHC) in a large cohort of gallstone disease (GSD) controls (n = 85) and GBC tissues (n = 85). Functional assays, including cell proliferation, wound healing, transwell invasion, and Western blot analyses of epithelial–mesenchymal transition (EMT) markers, were performed in the NOZ GBC cell line following siRNA-mediated SRI knockdown. IHC revealed that 67% of GBC cases exhibited positive staining whereas all the GSD cases exhibited negative staining of SRI, demonstrating a significant upregulation of SRI in GBC (p < 0.001). SRI knockdown resulted in reduced proliferative capacity and markedly impaired migration and invasion. Further, SRI knockdown decreased vimentin levels, indicating suppression of EMT. SRI is significantly overexpressed in GBC and promotes key oncogenic traits, including proliferation, migration, invasion, and EMT. These findings highlight SRI as a potential therapeutic target in GBC. Further validation in animal models may facilitate translation into clinical applications.

  • Open Access

    Stage-Specific miRNA Profiling Reveals Key Regulators of EMT and EGFR-TKI Resistance in Gallbladder Cancer

    by Neeraj Saklani, Puja Sakhuja, Surbhi Goyal, Anil Kumar Agarwal, Sarangadhara Appala Raju Bagadi, Poonam Gautam

    Background: Gallbladder cancer (GBC) is a highly aggressive malignancy characterized by a poor prognosis, particularly in its advanced stages. While microRNAs (miRNAs) regulate cancer progression, their specific role in the transition from early to advanced GBC is poorly understood. Methods: We performed miRNA expression profiling on 41 formalin-fixed paraffin-embedded (FFPE) tissues, including 10 gallstone disease (GSD) controls, 14 early-stage GBC (stage I and II), and 17 advanced-stage GBC cases (stage III and IV), using the NanoString nCounter platform. Differentially expressed miRNAs (DEMs) were identified followed by miRNA target identification using miRTarBase. Results: We identified 43 significantly dysregulated miRNAs in early-stage and 46 in advanced-stage GBC compared to controls. Based on the literature search, we found EMT-inhibiting miRNAs (miR-200 family) to be overexpressed in early stage and downregulated in advanced stages (miR-574-3p, miR-195-5p) in our study. Pathway analysis revealed significant enrichment of the ‘EGFR tyrosine kinase inhibitor resistance’ pathway in both the stages. The correlation of DEMs with clinicopathological features revealed that the expression of miR-361-3p and miR-423-5p was significantly associated with tumor grade (r = −0.605, p = 0.0003) and lymph node status (r = −0.621, p = 0.0001), respectively. Conclusions: This study identifies distinct miRNA signatures associated with GBC initiation and progression, offering insights into the molecular pathogenesis of the disease. Furthermore, functional studies of the miRNAs implicated in EMT and EGFR-TKI resistance may be conducted using GBC cell lines to dissect the precise roles of key miRNAs and explore their potential as novel therapeutic targets in GBC.

  • Beyond the Usual Barriers—A Primary Testicular Seminoma Arising in an Undescended Testis Presenting as a Colon Mass: A Case Report

    by Shilpi Thakur, Venkatesh Vaithiyam, Sanjeev Sachdeva, Bg Vageesh, Krishna Bhardwaj, Savita Arora, Puja Sakhuja, Surbhi Goyal

    Germ cell tumors (GCT) in men usually arise in the gonads, presenting as a testicular mass. GCT may rarely involve the gastrointestinal tract due to metastasis from the testicular tumor. GCT arising from an undescended testis and presenting primarily with gastrointestinal symptoms is extremely rare. We hereby present a primary testicular seminoma in a 51-year-old gentleman, presenting with gastrointestinal symptoms. Sigmoidoscopy showed a large ulcero-infiltrative growth (7 × 6 × 3 cm) in the cecum and proximal ascending colon. The growth was biopsied with a clinical suspicion of a primary colonic adenocarcinoma. The biopsy showed infiltration by a seminoma. A thorough clinicoradiological evaluation revealed right cryptorchidism in the patient. He later underwent right hemicolectomy which revealed an adherent remnant cryptorchid testis at ileocecal junction and colonic infiltration by seminoma. Though challenging to diagnose seminoma at an unusual site, accurate biopsy diagnosis can play a decisive role in planning the timely surgery and adjuvant chemotherapeutic options.

  • Open Access

    Comparative evaluation of a novel adhesive- Histoweld™ for immunohistochemistry: A non-inferiority study

    by Kanishk Gupta, Surbhi Goyal, Puja Sakhuja, Neelam Negi

    Objectives: To evaluate the performance of adhesive I (Histoweld ™ ) and compare it with routinely used adhesive II (poly-l-lysine). Materials and Methods: A total of 33 routinely used immunohistochemistry (IHC) antibodies specific for 11 different organs were selected for the study. Adhesive I (Histoweld ™ )- and adhesive II (poly-l-lysine)-coated slides were subjected to IHC, respectively, as per standard laboratory protocol in a blinded manner. The stained slides were evaluated for any tissue floatation, detachment, patchy loss, or folding of section. The staining was evaluated in terms of specificity, intensity, and signal: background noise. Positively charged slides served as reference. Results: Adhesive I-coated slides provided satisfactory tissue adhesion. There was no significant tissue loss during heat-induced epitope retrieval and other steps of IHC staining. Results showed optimal and comparable immunostaining in all (100%) selected antibodies. On comparative evaluation, IDH1, Bcl-2, and P53 showed stronger 3+ staining intensity with adhesive I-coated slides compared to adhesive II-coated slides. Bcl-2 showed mild 1+ homogenous background staining with adhesive I. No significant background noise interfering with the interpretation of result was seen with either of the adhesives. Conclusions: Adhesive I is a cost-effective and reliable alternative to adhesive II, with excellent adhesive performance and promising immunostaining results.

  • Open Access

    Lymph Node Metastasis in Gastrointestinal Carcinomas: A View from a Proteomics Perspective

    by Vaishali Jain, Puja Sakhuja, Anil Kumar Agarwal, Ravi Sirdeshmukh, Fouzia Siraj, Poonam Gautam

    Lymph node metastasis (LNM) is one of the major prognostic factors in human gastrointestinal carcinomas (GICs). The lymph node-positive patients have poorer survival than node-negative patients. LNM is directly associated with the recurrence and poor survival of patients with GICs. The early detection of LNM in patients and designing effective therapies to suppress LNM may significantly impact the survival of these patients. The rapid progress made in proteomic technologies could be successfully applied to identify molecular targets for cancers at high-throughput levels. LC-MS/MS analysis enables the identification of proteins involved in LN metastasis, which can be utilized for diagnostic and therapeutic applications. This review summarizes the studies on LN metastasis in GICs using proteomic approaches to date.